Top

Published in:

01-03-2017 | Review Article

Non-Surgical Ablative Therapy for Management of Small Renal Masses—Current Status and Future Trends

Authors: K. Farrag, S. Sriprasad

Published in: Indian Journal of Surgical Oncology | Issue 1/2017

Abstract

A large number of small renal masses (SRMs) with size less than 4 cm are being identified due to advances in diagnostic imaging. As the natural history of these tumours remains unknown, there is no reliable way to predict their behaviour or future growth. Although, partial nephrectomy is the gold standard for treatment of these tumours, ablative non-surgical therapies such as cryoablation and radiofrequency ablation provide a less invasive option of treatment with comparable oncological outcomes. In this systematic review, the principle, indications, methods of treatment, oncological control, complication and renal function of ablative therapies are critically reviewed. Cryotherapy utilizes the principle of inducing tissue destruction by freezing and thawing using argon and helium gasses, respectively. Radiofrequency ablation (RFA) works on the principle of tissue heating. Ablative treatments are particularly useful in the elderly patients, those with comorbidities or in patients with SRMs in solitary kidneys or renal impairment. Ablative therapies have less procedure-related complications and have promising medium-term oncological outcome. Longer-term results are accumulating. Cryotherapy may be a better modality for oncological control than RFA. Ablative therapy has emerged as a viable treatment options for SRMs with recurrence free survival rates approaching that of extirpative surgery. However, there is no consensus in the literature on the best selection criteria and this needs further refinement. Prospective long-term data with regards to oncological control is still needed

Chow WH, Devesa SS, Warren JL, Fraumeni JF (1999) Rising incidence of renal cell cancer in the United States. JAMA 281(17):1628–1631CrossRefPubMed

Crispen PL, Uzzo RG (2007) The natural history of untreated renal masses. BJU Int 99(5 Pt B):1203–1207. doi:10.1111/j.1464-410X.2007.06811.x CrossRefPubMed

Chawla SN, Crispen PL, Hanlon AL, Greenberg RE, Chen DYT, Uzzo RG (2006) The natural history of observed enhancing renal masses: meta-analysis and review of the world literature. J Urol 175(2):425–431. doi:10.1016/S0022-5347(05)00148-5 CrossRefPubMed

Lee CT, Katz J, Shi W, Thaler HT, Reuter VE, Russo P (2000) Surgical management of renal tumors 4 cm. Or less in a contemporary cohort. J Urol 163(3):730–736CrossRefPubMed

Lau WK, Blute ML, Weaver AL, Torres VE, Zincke H (2000) Matched comparison of radical nephrectomy vs nephron-sparing surgery in patients with unilateral renal cell carcinoma and a normal contralateral kidney. Mayo Clin Proc 75(12):1236–1242CrossRefPubMed

McKiernan J, Simmons R, Katz J, Russo P (2002) Natural history of chronic renal insufficiency after partial and radical nephrectomy. Urology 59(6):816–820CrossRefPubMed

Gill IS, Kavoussi LR, Lane BR, Blute ML, Babineau D, Colombo JR, Novick AC (2007) Comparison of 1,800 laparoscopic and open partial nephrectomies for single renal tumors. J Urol 178(1):41–46CrossRefPubMed

Hadjipavlou M, Khan F, Fowler S, Joyce A, Keeley FX, Sriprasad S (2016) Partial vs radical nephrectomy for T1 renal tumours: an analysis from the British Association of Urological Surgeons Nephrectomy Audit. BJU Int 117(1):62–71CrossRefPubMed

Gill IS (2003) Minimally invasive nephron-sparing surgery. Urologic Clin North Am 30(3):551–579CrossRef

10.

Zargar H, Atwell TD, Cadeddu JA, Jean J, Janetschek G, Kaouk JH, Matin SF, Polascik TJ, Zargar-Shoshtari K, Thompson RH (2016) Cryoablation for small renal masses: selection criteria, complications, and functional and oncologic results. Eur Urol 69(1):116–128CrossRefPubMed

11.

Khan F, Sriprasad S, Keeley FX (2012) Cryosurgical ablation for small renal masses, current status and future prospects. Brit J Med Surg Urol 5:S28–S34CrossRef

12.

Sriprasad S. and Marsh H. (2011). The management of small renal tumours by ablative therapies. INTECH Open Access Publisher

13.

Rewcastle JC, Sandison GA, Saliken JC, Donnelly BJ, McKinnon JG (1999) Considerations during clinical operation of two commercially available cryomachines. J Surg Oncol 71(2):106–111CrossRefPubMed

14.

Acker JP, Larese A, Yang H, Petrenko A, McGann LE (1999) Intracellular ice formation is affected by cell interactions. Cryobiology 38(4):363–371. doi:10.1006/cryo.1999.2179 CrossRefPubMed

15.

Bischof JC, Smith D, Pazhayannur PV, Manivel C, Hulbert J, Roberts KP (1997) Cryosurgery of dunning AT-1 rat prostate tumor: thermal, biophysical, and viability response at the cellular and tissue level. Cryobiology 34(1):42–69. doi:10.1006/cryo.1996.1978 CrossRefPubMed

16.

Daum PS, Bowers WD, Tejada J, Hamlet MP (1987) Vascular casts demonstrate microcirculatory insufficiency in acute frostbite. Cryobiology 24(1):65–73CrossRefPubMed

17.

Clarke DM, Robilotto AT, Rhee E, VanBuskirk RG, Baust JG, Gage AA, Baust JM (2007) Cryoablation of renal cancer: variables involved in freezing-induced cell death. Technol Cancer Res Treat 6(2):69–79CrossRefPubMed

18.

Janzen N, Zisman A, Pantuck AJ, Perry K, Schulam P, Belldegrun AS (2002) Minimally invasive ablative approaches in the treatment of renal cell carcinoma. Current Urol Rep 3(1):13–20CrossRef

19.

Chodez M, Fiard G, Arnoux V, Descotes J-L, Long J-A (2015) Ablative treatments in localised renal cancer: literature review in 2014. Progrès en urologie : journal de l’Association française d'urologie et de la Société française d'urologie 25(9):499–509CrossRef

20.

Kunkle DA, Uzzo RG (2008) Cryoablation or radiofrequency ablation of the small renal mass: a meta-analysis. Cancer 113(10):2671–2680. doi:10.1002/cncr.23896 CrossRefPubMedPubMedCentral

21.

Autorino R, Haber G-P, White MA, Stein RJ, Kaouk JH (2010) New developments in renal focal therapy. J Endourol/Endourological Soc 24(5):665–672. doi:10.1089/end.2009.0643 CrossRef

22.

Laguna MP, Beemster P, Kumar V, Kumar P, Klingler HC, Wyler S, de la Rosette JJ (2009) Perioperative morbidity of laparoscopic cryoablation of small renal masses with ultrathin probes: a European multicentre experience. Eur Urol 56(2):355–361CrossRefPubMed

23.

Lokken RP, Gervais DA, Arellano RS, Tuncali K, Morrison PR, Tatli S et al (2007) Inflammatory nodules mimic applicator track seeding after percutaneous ablation of renal tumors. AJR Am J Roentgenol 189(4):845–848. doi:10.2214/AJR.07.2015 CrossRefPubMed

24.

Nielsen TK, Lagerveld BW, Keeley F, Lughezzani G, Sriprasad S, Barber NJ, Hansen LU, Larcher A, Guazzoni G, Van Der Zee JA, Ismail M (2016) 1094 outcomes after laparoscopic assisted renal cryoablation: a retrospective EuRECA multinational analysis. Eur Urol Suppl 3(15):e1094–e1094aCrossRef

25.

Sisul DM, Liss MA, Palazzi KL, Briles K, Mehrazin R, Gold RE, Masterson JH, Mirheydar HS, Jabaji R, Stroup SP, James OL (2013) RENAL nephrometry score is associated with complications after renal cryoablation: a multicenter analysis. Urology 81(4):775–780CrossRefPubMed

26.

Beemster P, Phoa S, Wijkstra H, de la Rosette J, Laguna P (2008) Follow-up of renal masses after cryosurgery using computed tomography; enhancement patterns and cryolesion size. BJU Int 101(10):1237–1242. doi:10.1111/j.1464-410X.2007.07437.x CrossRefPubMed

27.

Berger A, Kamoi K, Gill IS, Aron M (2009) Cryoablation for renal tumors: current status. Curr Opin Urol 19(2):138–142. doi:10.1097/MOU.0b013e328323f618 CrossRefPubMed

28.

Johnson S, Pham KN, See W, Begun FP, Langenstroer P (2014) Laparoscopic cryoablation for clinical stage T1 renal masses: long-term oncologic outcomes at the Medical College of Wisconsin. Urology 84(3):613–618. doi:10.1016/j.urology.2014.03.055 CrossRefPubMed

29.

Kunkle DA, Egleston BL, Uzzo RG (2008) Excise, ablate or observe: the small renal mass dilemma—a meta-analysis and review. J Urol 179(4):1227–1233 . doi:10.1016/j.juro.2007.11.047discussion 1233–4CrossRefPubMed

30.

Woldu SL, Thoreson GR, Okhunov Z, Ghandour R, Rothberg MB, RoyChoudhury A et al (2015) Comparison of renal parenchymal volume preservation between partial nephrectomy, cryoablation, and radiofrequency ablation using 3D volume measurements. J Endourol/ Endourological Soc 29(8):948–955. doi:10.1089/end.2014.0866 CrossRef

31.

Michaels MJ, Rhee HK, Mourtzinos AP, Summerhayes IC, Silverman ML, Libertino JA (2002) Incomplete renal tumor destruction using radio frequency interstitial ablation. J Urol 168(6):2406–2409 . doi:10.1097/01.ju.0000037915.89846.b6discussion 2409–10CrossRefPubMed

32.

Altunrende F, Autorino R, Hillyer S, Yang B, Laydner H, White MA et al (2011) Image guided percutaneous probe ablation for renal tumors in 65 solitary kidneys: functional and oncological outcomes. J Urol 186(1):35–41. doi:10.1016/j.juro.2011.03.024 CrossRefPubMed

33.

Khan F, Mahmalji W, Madaan S, Dickinson IK, Keeley FX, Lagerveld BW, Sriprasad S, (2013). Multi-institutional analysis of renal function following cryoablation of small renal masses in solitary kidneys. In BJU INTERNATIONAL (Vol. 111, pp. 37–37). 111

34.

Weight CJ, Fergany AF, Gunn PW, Lane BR, Novick AC (2008) The impact of minimally invasive techniques on open partial nephrectomy: a 10-year single institutional experience. J Urol 180(1):84–88. doi:10.1016/j.juro.2008.03.049 CrossRefPubMed

35.

Ramirez D, Ma YB, Bedir S, Antonelli JA, Cadeddu JA, Gahan JC (2014) Laparoscopic radiofrequency ablation of small renal tumors: long-term oncologic outcomes. J Endourol 28(3):330–334CrossRefPubMed

36.

Levinson AW, Su L-M, Agarwal D, Sroka M, Jarrett TW, Kavoussi LR, Solomon SB (2008) Long-term oncological and overall outcomes of percutaneous radio frequency ablation in high risk surgical patients with a solitary small renal mass. J Urol 180(2):499–504 . doi:10.1016/j.juro.2008.04.031discussion 504CrossRefPubMed

37.

Stern JM, Svatek R, Park S, Hermann M, Lotan Y, Sagalowsky AI, Cadeddu JA (2007) Intermediate comparison of partial nephrectomy and radiofrequency ablation for clinical T1a renal tumours. BJU Int 100(2):287–290. doi:10.1111/j.1464-410X.2007.06937.x CrossRefPubMed

38.

Tracy CR, Raman JD, Donnally C, Trimmer CK, Cadeddu JA (2010) Durable oncologic outcomes after radiofrequency ablation. Cancer 116(13):3135–3142CrossRefPubMed

39.

Psutka SP, Feldman AS, McDougal WS, McGovern FJ, Mueller P, Gervais DA (2013) Long-term oncologic outcomes after radiofrequency ablation for T1 renal cell carcinoma. Eur Urol 63(3):486–492CrossRefPubMed

40.

Thompson RH, Atwell T, Schmit G, Lohse CM, Kurup AN, Weisbrod A et al (2015) Comparison of partial nephrectomy and percutaneous ablation for cT1 renal masses. Eur Urol 67(2):252–259. doi:10.1016/j.eururo.2014.07.021 CrossRefPubMed

41.

Kutikov A, Smaldone MC, Uzzo RG (2015) Focal therapy for treatment of the small renal mass: dealer’s choice or a therapeutic gamble? Eur Urol 67(2):260–261. doi:10.1016/j.eururo.2014.08.034 CrossRefPubMed

42.

Marberger M, Schatzl G, Cranston D, Kennedy JE (2005) Extracorporeal ablation of renal tumours with high-intensity focused ultrasound. BJU Int 95(Suppl 2):52–55. doi:10.1111/j.1464-410X.2005.05200.x CrossRefPubMed

Title: Non-Surgical Ablative Therapy for Management of Small Renal Masses—Current Status and Future Trends
Authors: K. Farrag
S. Sriprasad
Publication date: 01-03-2017
Publisher: Springer India
Published in: Indian Journal of Surgical Oncology / Issue 1/2017
Print ISSN: 0975-7651
Electronic ISSN: 0976-6952
DOI: https://doi.org/10.1007/s13193-016-0598-x

At a glance: The STEP trials

Springer Medicine

Non-Surgical Ablative Therapy for Management of Small Renal Masses—Current Status and Future Trends

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2017

Management of Adrenal Masses

Bilateral Aldosterone-Producing Adrenocortical Carcinoma: a Rare Entity

Primary Testicular Leiomyosracoma with Local Recurrence: a Case Report

Organ Preservation Surgery for Carcinoma Penis

Prevention Technique of Postoperative Inguinal Hernia in Patients Undergoing Radical Prostatectomy for Localized Prostate Cancer

Molecular and Functional Diagnostic Tools in Precision Oncology for Urological Malignancies